Adenosine, astrocyte metabotropic glutamate receptors (mGluRs), and epoxyeicosatrienoic acids (EETs) have been implicated in neurovascular coupling. Although A 2A and A 2B receptors mediate cerebral vasodilation to adenosine, the role of each receptor in the cerebral blood flow (CBF) response to neural activation remains to be fully elucidated. In addition, adenosine can amplify astrocyte calcium, which may increase arachidonic acid metabolites such as EETs. The interaction of these pathways was investigated by determining if combined treatment with antagonists exerted an additive inhibitory effect on the CBF response. During whisker stimulation of anesthetized rats, the increase in cortical CBF was reduced by approximately half after individual administration of A 2B , mGluR and EET antagonists and EET synthesis inhibitors. Combining treatment of either a mGluR antagonist, an EET antagonist, or an EET synthesis inhibitor with an A 2B receptor antagonist did not produce an additional decrement in the CBF response. Likewise, the CBF response also remained reduced by B50% when an EET antagonist was combined with an mGluR antagonist or an mGluR antagonist plus an A 2B receptor antagonist. In contrast, A 2A and A 3 receptor antagonists had no effect on the CBF response to whisker stimulation. We conclude that (1) adenosine A 2B receptors, rather than A 2A or A 3 receptors, play a significant role in coupling cortical CBF to neuronal activity, and (2) the adenosine A 2B receptor, mGluR, and EETs signaling pathways are not functionally additive, consistent with the possibility of astrocytic mGluR and adenosine A 2B receptor linkage to the synthesis and release of vasodilatory EETs.
Introduction
The coupling of increased cerebral blood flow (CBF) to increased neuronal activity is of fundamental physiologic importance. Signaling pathways involved in the functional hyperemic response include neuronally derived nitric oxide (NO), cyclooxygenase (COX) activity, adenosine, and the epoxyeicosatrienoic acid (EET) products of cytochrome P450 metabolism of arachidonic acid . In the cerebral cortex, NO is viewed as a modulator, rather than mediator, of the hyperemic response (Lindauer et al, 1999) . Cyclooxygenase-2, which is constitutively expressed in selected cortical neurons (Wang et al, 2005) , has been implicated as a mediator of the CBF response to whisker stimulation in mouse (Niwa et al, 2000) . Cyclooxygenase-1 has been implicated in cortical vasodilation in response to increased Ca 2 + in mouse astrocyte end-feet (Takano et al, 2006) , although COX-1 gene deletion or inhibition does not reduce the CBF response to vibrissal stimulation (Niwa et al, 2001 ). In addition, astrocytes in rats express cytochrome P450 2C11 (Alkayed et al, 1996; Peng et al, 2004) , which possesses expoxygenase activity and releases EETs in response to glutamate (Alkayed et al, 1997) . Inhibition of EET synthesis in rats attenuates the CBF response to vibrissal (Peng et al, 2002) and forepaw stimulation (Peng et al, 2004) .
One hypothesis is that release of the neurotransmitter glutamate stimulates metabotropic glutamate receptors (mGluRs) on astrocytes to increase Ca 2 + , mobilize arachidonic acid, and stimulate production and release of COX products (Zonta et al, 2003) and EETs from astrocytes (Alkayed et al, 1997; Gebremedhin et al, 2003; Metea and Newman, 2006) , which then mediate vasodilation (Gebremedhin et al, 1992; Takano et al, 2006) .
A role for adenosine is supported by the observations that adenosine deaminase and the nonselective adenosine antagonist theophylline attenuated the CBF response to whisker stimulation by approximately 40% in the rat (Dirnagl et al, 1994) and that theophylline attenuated pial arteriolar dilation in response to sciatic nerve stimulation (Ko et al, 1990) . However, the role of specific adenosine receptors in the CBF response is unclear. Dilation of cerebral arterioles to exogenous adenosine is attenuated by the selective A 2A antagonist 4-(2-[7-amino-2-(2-furyl) [1, 2, 4] triazolo [2,3-a] [1,3,5] triazin-5-yl-amino]ethyl)phenol (ZM-241385) and by the selective A 2B antagonist alloxazine (Ngai et al, 2001; Shin et al, 2000) . Moreover, ZM-241385 inhibits pial arteriolar dilation to sciatic nerve stimulation and to glutamate (Iliff et al, 2003; Meno et al, 2001) , and ZM-241385 and alloxazine each attenuate pial arteriolar dilation to activation of AMPA receptors (Ohata et al, 2006) . Whether A 2A and A 2B receptors contribute to whisker stimulation-evoked CBF response, which largely depends on dilation of intraparenchymal arterioles, has not been demonstrated. Moreover, various adenosine receptors are functional in astrocytes (Fields and Burnstock, 2006) , and A 2B receptors appear to be particularly important in amplifying ATP-dependent increases in intracellular Ca 2 + (Alloisio et al, 2004; Jimenez et al, 1999; Pilitsis and Kimelberg, 1998) . Thus, it is possible that adenosine may act upstream from vascular smooth muscle to increase astrocyte Ca 2 + , which could act in concert with mGluR-mediated Ca 2 + increase to promote vasodilation that is dependent on arachidonic acid metabolites. In addition, expression of A 3 receptors has been described in cerebral vessels (Di Tullio et al, 2004) , but their function has not been well delineated (Ngai et al, 2001) .
Because adenosine antagonists, mGluR antagonists, and epoxygenase inhibitors do not completely block the CBF response to cortical activation, these mechanisms may act by parallel, additive pathways. The purpose of this study was to determine (1) whether adenosine A 2A , A 2B , and A 3 receptors contribute to the increase in CBF during whisker stimulation, (2) whether the attenuating effect of inhibiting the cytochrome P450 epoxygenase pathway on the CBF response to cortical activation depends on adenosine receptor or mGluR activation, and (3) whether inhibiting adenosine receptor and mGluR results in additive inhibition of the CBF response. The specific hypotheses tested were as follows: (1) the CBF response to whisker stimulation is attenuated by the A 2A antagonists ZM-241385 and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4, 3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH-58261), the A 2B antagonists alloxazine and 8-[4-[((4-cyanophenyl)-carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine (MRS-1754), and A 3 antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(7)-dihydropyridine-3,5-dicarboxylate (MRS-1191); (2) blocking the cytochrome P450 epoxygenase pathway produces additional attenuation of the CBF response in the presence of A 2A , A 2B , and mGluR antagonists; and (3) blocking the particular adenosine receptor that contributes to the CBF response produces additional inhibition of the CBF response in the presence of an mGluR antagonist.
Previous work used the EETs synthesis inhibitor N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH) or miconazole to reduce the CBF response to functional activation (Peng et al, 2002 (Peng et al, , 2004 . Because preformed, stored EETs can be released from the phospholipid membrane (Shivachar et al, 1995) , the EET antagonists 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) and 14,15-epoxyeicosa-5(Z)-enoic methylsulfonylimide (14,15-EEZE-mSI) were also used to confirm the role of EETs in this study (Gauthier et al, 2002 (Gauthier et al, , 2003 and to test the interaction between EETs and adenosine pathways.
Methods

Surgical Procedures
All procedures were approved by the Johns Hopkins University Animal Care and Use Committee. The surgical preparation and experimental design are similar to that described previously (Peng et al, 2002) . Male Wistar rats (230 to 300 g) were anesthetized with halothane and mechanically ventilated through a tracheostomy with approximately 30% O 2 and 1.5% halothane. A femoral artery was catheterized for arterial blood pressure measurement and for analysis of pH and partial pressure of CO 2 (P CO2 ) and O 2 (P O2 ). Rectal temperature was maintained near 371C. The scalp and muscle over the parietal and temporal bone were retracted. The bone was thinned by drilling a 5-mm region overlying the whisker barrel sensory cortex (2 to 3 mm posterior and 7 mm lateral from bregma). Cortical perfusion in this region was measured with a laser-Doppler flow (LDF) probe (Perimed, North Royalton, OH) kept in a fixed position over the thinned skull with a stereotactic head holder. For local superfusion of drugs over the cortical surface, a PE-10 catheter was finely tapered to a diameter of B120 mm and the tip was gently placed under the dura mater at a site 3 mm dorsal and posterior to the flow probe site. Artificial cerebrospinal fluid (CSF) was superfused and passively drained from a small hole in the skull and dura located approximately 2 to 3 mm ventral and anterior to the recording site. Halothane was discontinued, and a postsurgical sedation level of anesthesia was maintained for the duration of the experiment by administration of warmed a-chloralose (25 to 33 mg/kg, intraperitoneal, plus 12 to 15 mg/kg/h). This dose prevented spontaneous muscle movement and arterial hypertension.
Experimental Protocol
Subarachnoid superfusion of artificial CSF was initiated 1 h after discontinuing halothane and continued throughout the experiment at a rate of 5 mL/min. The LDF response to whisker stimulation commenced at least 1 h after starting the CSF superfusion. Whisker stimulation was achieved by mechanical displacement of multiple whiskers inserted through a screen mesh connected to a solenoid-driven piston (Peng et al, 2002) . After recording LDF for a 60-sec baseline period for each stimulation trial, the whiskers were displaced at 5 Hz for 60 secs. The LDF was averaged over 1-sec intervals. The percentage change in LDF was calculated from the preceding 60-sec baseline period and was averaged on a second-by-second basis over three trials spaced 2 to 3 mins apart. After obtaining the records of three trials with CSF superfusion at the end of the first hour of the protocol, an antagonist/inhibitor was administered. Three trials of whisker stimulation were repeated after 1 h of superfusion of the drug. After the second hour of the protocol, either the antagonist/inhibitor superfusion continued for another hour, or a second drug was administered while the first drug continued to be superfused. After the third hour of the protocol, three trials of whisker stimulation were repeated.
To evaluate the time course and steady-state concentration of superfused drugs in the CSF, [
3 H]-ZM-241385 (2 mCi/mL) was infused in CSF in four rats with subarachnoid superfusion. A well was constructed with acrylic cement around the outflow hole. Outflow CSF samples were collected at 5-min intervals over a 1-h period, and the concentration of radioactivity was analyzed as a percentage of the inflow concentration. Results were compared with CSF outflow from a standard closed cranial window (B200 mL volume) superfused with [ The concentration of the DMSO and ethanol vehicles used in these experiments did not affect the LDF response to whisker stimulation. The LDF response to whisker stimulation was examined in 18 groups of rats that received these drugs alone or in combination. An additional two groups received lower doses of alloxazine to obtain a dose-response relationship.
To determine if drugs that reduced the evoked LDF response were capable of reducing evoked potentials, somatosensory evoked potentials were examined. Electrical stimulation of the forepaw was used to maximize the evoked potential and to provide a precise triggering time for gating the averaging of evoked potentials, as described previously (Peng et al, 2002) . Through subcutaneous electrodes, the foreleg was stimulated with 150-ms pulses of 2-mA current at a rate of 2.9 pulses/sec. The time-gated average of 128 repetitions of evoked potentials was recorded with a silver ball electrode placed over the dura near the forelimb primary sensory cortex. The amplitude between the first positive and first negative waves was measured in triplicate after 1 h of CSF superfusion and again after 1 h of superfusion of 30 mmol/L 14,15-EEZE, superfusion of 100 mmol/L AIDA, 1 mg/kg, intravenous, plus superfusion of 1 mmol/L ZM-241385, or 1 mg/kg, intravenous, plus superfusion of 1 mmol/L alloxazine. The percentage change in the primary wave of the evoked potential amplitude after drug administration was compared with the percentage change in a time-control group that was superfused with CSF for the second hour.
To determine the efficacy and selectivity of ZM-241385 and alloxazine in this model, the LDF responses to an A 2A agonist 4-[2- [[6-amino-9-(N-ethyl- (CGS-21680; Tocris) and an A 2 agonist 5 0 -N-ethylcarboxamido-adenosine (NECA; Sigma) were tested. Although highly selective A 2B agonists are not currently available, alloxazine has been shown to be more potent than ZM-241385 in inhibiting pial arteriolar dilation to NECA (Shin et al, 2000) . In one experiment, three groups were treated with vehicle (0.01% DMSO in CSF), ZM-241385, or alloxazine starting 1 h before superfusion of 0.3 mmol/L CGS-21680 for 1 h. In a second experiment, three groups were treated with vehicle (0.03% DMSO), ZM-241385, or alloxazine starting 1 h before superfusion of 10 mmol/L NECA for 1 h. Superfusion of the antagonist continued during the superfusion of the agonist.
Isolated Middle Cerebral Arteries
Rat middle cerebral arterial segments (8 to 10 mm in length and 200 to 250 mmol/L outer diameter) were isolated, placed in a perfusion chamber, cannulated at both ends with glass micropipettes, and secured in place with 8-0 polyethylene suture using a stereo microscope. Side branches of the arteries were tied off with 10-0 polyethylene suture. The arterial segments were perfused and superfused with physiologic salt solution (Gebremedhin et al, 1992) aerated with a 21% O 2 -5% CO 2 gas mixture (balance N 2 ) and were maintained at 371C and pH 7.4. A bolus of air was passed through the lumen to cause damage to the endothelium of the arterial segments. The inflow cannula was connected in series with a volume reservoir and a pressure transducer to allow continuous monitoring of transmural pressure. Internal diameter of the arteries was measured using a video-microscopy system composed of a television camera and a videomicrometer, as described previously (Gebremedhin et al, 1992) . After an equilibration period of 15 mins, the cannulated arteries were pressurized to 80 mm Hg, and maintained at this pressure throughout the course of the experiment. After an additional 15 mins equilibration, the vessels were preconstricted with 30 mmol/L serotonin to produce additional tone for measuring the relaxation response to EETs and acetylcholine. The relaxation response to 1 mmol/L acetylcholine was determined in attempt to judge the integrity of the endothelium. Arterial segments that constricted to serotonin and failed to dilate in response to acetylcholine were studied. After repeated washout and a further 30 mins equilibration of the arterial segments, the effects of 100 and 300 nmol/L 14,15-EET before and after treatment of the arterial segments with the EETs antagonist 14,15-EEZE-mSI (10 mmol/L) on the internal arterial diameter was determined.
Statistical Analysis
The percentage change in LDF was averaged over the 60-sec period of whisker stimulation. For each rat, an average percentage response was obtained from three trials for each hourly intervention. Within each group, the average percentage responses at 1, 2, and 3 h were tested for an effect of treatment by repeated measures analysis of variance. If the F-value was significant, differences in individual mean values at each time point were compared by paired t-test with Bonferroni correction. To determine if drug treatment altered baseline LDF without whisker stimulation, the percentage change in baseline LDF from the initial value at 1 h was calculated in each drugtreatment group and compared with the percentage change in baseline LDF in the time-control group by t-test. All values are presented as means 7s.d. The level of significance was set at P < 0.05.
Results
To determine the degree to which endogenous CSF dilutes drugs infused at a rate of 5 mL/min into the subarachnoid space, radiolabeled ZM-241385 was infused. The concentration of radioactivity in the outflow from the drainage hole on the opposite side of the LDF monitoring site reached 8073% of the inflow concentration by the 10 to 15-min collection period and 9576% by the 55 to 60-min period ( Figure 1 ). Superfusion of a closed cranial window at a rate of 200 mL/min resulted in an outflow concentration equivalent to the inflow concentration by the 10 to 15-min collection period. Over the 1-h period, the area under the curve of the outflow concentration with subarachnoid superfusion was 84% of that of the cranial window outflow concentration. A 1-h period of subarachnoid superfusion was used to permit penetration of drugs into tissue sensitive to flowmetry by the LDF probe (Irikura et al, 1994) .
Within each of the experimental groups subjected to whisker stimulation trials at 1-h intervals, mean arterial blood pressure and PaCO 2 remained stable in the physiologic range (Table 1) . Arterial pH was in the range of 7.35 to 7.45, PaO 2 was maintained at 130 to 150 mm Hg, arterial hemoglobin concentration was in the range of 10 to 13 g/dL, and rectal temperature was in the range of 36.5 to 37.51C.
In the absence of whisker stimulation, baseline LDF remained unchanged at the second and third hours of CSF superfusion of cortex in the timecontrol group (Table 2) . Stoppage of CSF superfusion did not change baseline LDF. As expected, the group superfused with L-NNA exhibited a decrease in baseline LDF. Except for a 29% increase in baseline LDF after 2 h of superfusion with 14,15-EEZE, none of the other antagonists and inhibitors produced a significant change in baseline LDF, compared with the time-control group.
The percentage change in LDF averaged over three trials of 60 secs of whisker stimulation did not change during 3 h of CSF superfusion in the timecontrol group ( , as a fraction of the inflow concentration, in rats with subarachnoid superfusion at 5 mL/min (n = 4) or with a closed cranial window superfused at 200 mL/min (n = 4) for 1 h. The area under the curve for subarachnoid superfusion was 84% of that with cranial window superfusion. n = 6). However, administration of the adenosine A 2B antagonist alloxazine produced a dose-dependent reduction of the LDF response to whisker stimulation. At a dose of 0.1 mg/kg, intravenous, plus 0.1 mmol/L superfusion, the response was not significantly attenuated (11177% of CSF baseline response; n = 2). At a dose of 0.3 mg/kg, intravenous, plus 0.3-mmol/L superfusion, the response was marginally reduced (P < 0.10) to 86717% of the CSF baseline response (n = 7). At a dose of 1 mg/kg, intravenous, plus 1-mmol/L superfusion, the response was significantly reduced to 58725% of the CSF baseline response (n = 6; Figure 2C ). The latter dose was used in other groups with combined treatments. Higher doses of alloxazine were not tested because of concern of nonselectivity and because this dose antagonizes dilation of pial arterioles to exogenous adenosine (Shin et al, 2000) and dilation to activation of AMPA receptors (Ohata et al, 2006) . Pial arteriolar dilation mediated by adenosine A 2B receptors is thought to be associated with increased NO synthase activity (Shin et al, 2000) . Superfusion of 1 mmol/L L-NNA attenuated the LDF response to whisker stimulation ( Figure 2D ; n = 6), in agreement with others (Lindauer et al, 1999) . Administration of alloxazine with L-NNA resulted in no additional decrease in the LDF response to whisker stimulation.
To determine if the doses of ZM-241385 and alloxazine were adequate for blocking the LDF responses to adenosine receptor activation, LDF 
Groups are defined by treatment at 2 h/combined treatment at 3 h. AIDA, 1-aminoindan-1,5-dicarboxylic acid; L-NNA, N ù -nitro-L-arginine; 14,15-EEZE, 14,15-epoxyeicosa-5(Z)-enoic acid; 14,15-EEZE-mSI, 14,15-epoxyeicosa-5(Z)-enoic methylsulfonylimide; MRS-1191, 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(7)-dihydropyridine-3,5-dicarboxylate; MRS-1754, 8-[4-[((4-cyanophenyl) responses to the adenosine receptor agonists CGS-21680 and NECA were evaluated. Superfusion of 0.3 mmol/L CGS-21680 increased LDF by 64710% by 35 mins and the increase remained stable through 60 mins of superfusion ( Figure 3A) . Treatment with 1 mg/kg of ZM-241385 plus 1 mmol/L superfusion starting 1 h before CGS-21680 superfusion nearly blocked the increase in LDF seen at 35 mins of CGS-21680 superfusion (577%), and the response remained suppressed through 60 mins. In contrast, treatment with 1 mg/kg of alloxazine plus 1 mmol/L superfusion had no significant effect on the LDF response to CGS-21680 (58713% at 35 mins). Superfusion of 10 mmol/L NECA increased LDF by 2676% by 20 mins and the increase remained stable through 60 mins of superfusion ( Figure 3B ). Treatment with ZM-241385 had no effect on the increase in LDF (2471% at 20 mins). However, treatment with alloxazine markedly blunted the response to NECA throughout the 60-min superfusion period (4 74% at 20 mins).
Another A 2A antagonist SCH-58261 was tested to assure that the lack of effect on the whisker stimulation response was not specific for ZM-241385. Moreover, SCH-58261 was administered only systemically without placement of a subarachnoid catheter to assure that catheter placement was not responsible for the lack of effect by ZM-241385. A dose of 0.1 mg/kg + 0.1 mg/kg/h, intravenous, which is one order of magnitude greater than the dose found to be neuroprotective in rats (Melani et al, 2006) , did not change the LDF response to whisker stimulation ( Figure 4A ; n = 6). To confirm the inhibitory effect of alloxazine, the chemically distinct A 2B antagonist MRS-1754 was tested. A dose of 1 mg/kg, intravenous, plus 1 mmol/L superfusion A B D C Figure 2 Percentage change of cortical LDF (7s.d.) averaged over a 60-sec period of whisker stimulation at 1-h superfusion of CSF and (A) after an additional 2 h of continued CSF superfusion(n = 12) or (B) after an additional 2 h administration of the A 2A antagonist ZM-241385 (n = 6), or (C) the A 2B antagonist alloxazine ( n = 6). In D, the NO synthase inhibitor L-NNA was superfused during the second and third hours and alloxazine administration was combined with L-NNA during the third hour (n = 6). *P < 0.05 from the 1-h control response. Figure 3 Percentage change of cortical LDF (7s.d.) averaged over 5-min periods during 1 h of subarachnoid superfusion of (A) 0.3 mmol/L CGS-21680 or (B) 10 mmol/L NECA after 1 h pretreatment with vehicle (n = 4), 1 mg/kg, intravenous, plus 1 mmol/L CSF superfusion of ZM-241385 (n = 4), or 1 mg/kg, intravenous, plus 1 mmol/L CSF superfusion of alloxazine (n = 4). *P < 0.05 from vehicle group.
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of MRS-1754 significantly attenuated the LDF response to whisker stimulation ( Figure 3B ; n = 7). However, the A 3 antagonist MRS-1191 (1 mmol/L superfusion) had no significant effect on the LDF response ( Figure 4C ; n = 5). Systemic administration of MRS-1191 was not used because of effects on blood pressure.
Previous work has demonstrated that the EET synthesis inhibitors MS-PPOH and miconazole at doses of 20 mmol/L reduced the LDF response to whisker stimulation (Peng et al, 2002) and electrical stimulation of the forepaw (Peng et al, 2004) . This inhibitory effect was confirmed in this study. Superfusion of 20 mmol/L MS-PPOH ( Figure 5A ; n = 6) or miconazole ( Figure 5B ; n = 6) for 1 h decreased the LDF response to whisker stimulation to 62722% and to 54718% of the baseline response, respectively. No further reductions in the response occurred after the second hour of superfusion. The EETs antagonist 14,15-EEZE-mSI, at a dose of 10 mmol/L, has been reported to inhibit relaxation of coronary artery rings to 14,15-EET (Gauthier et al, 2003) . In isolated rat middle cerebral artery, 10 mmol/ L of 14,15-EEZE-mSI was found to reduce dilation to 100 and 300 nmol/L 14,15-EET ( Figure 5C ; n = 4). For in vivo experiments, a slightly higher dose of 30 mmol/L was used to help ensure adequate penetration into cerebral cortex. Superfusion of cortex with 30 mmol/L 14,15-EEZE-mSI for 1 h decreased the LDF response to whisker stimulation to 63723% of the CSF response. The response after the second hour of superfusion was not significantly different from the first hour's response ( Figure 5D ; n = 7). Likewise, 14,15-EEZE (30 mmol/L) reduced the response to 55720% of the baseline response, with no further change after the second hour of superfusion ( Figure 5E ; n = 6). Because 14,15-EEZE can antagonize the action of all four regioisomers (Gauthier et al, 2002) , this antagonist was used in further experiments.
Knowing that the second hour of superfusion of alloxazine, 14,15-EEZE, or MS-PPOH alone did not produce a further attenuation of the response, in additional groups studied, a second drug was added 1 h after the start of superfusion of the first drug to determine if combined drug treatment would produce additional attenuation of the response. In the presence of alloxazine, addition of 14,15-EEZE to the superfusate did not produce greater attenuation of the LDF response, compared with alloxazine alone (Figure 6 ; n = 8). Moreover, in the presence of MS-PPOH, administration of alloxazine did not produce additional attenuation of the response (Figure 7 ; n = 6). In the presence of ZM-214385, which did not attenuate the response by itself, addition of 14,15-EEZE to the superfusate did reduce the LDF response (Figure 8 ; n = 6) by an amount similar to 14,15-EEZE alone ( Figure 5E ). The time course of the mean and s.d. of the percentage changes in LDF from a 60-sec baseline period are shown in Figures 6-8 on a second-by-second basis for each group of rats. During the control response, LDF began to increase at 1 to 2 secs from the onset of whisker stimulation and reached over 80% of the steady-state response within 5 secs. Alloxazine, MS-PPOH, and 14,15-EEZE reduced the steady-state response, but did not delay the initial increase in LDF.
Superfusion of 100 mmol/L of the mGluR antagonist AIDA reduced the LDF response to 53718% of the control response, with no further reduction during the second hour of superfusion (45710% of control response; n = 6). In the presence of AIDA, addition of alloxazine did not produce a further reduction of the steady-state LDF response or a substantial delay in the response (Figure 9 ; n = 6). Figure 4 Percentage change of cortical LDF (7s.d.) averaged over a 60-sec period of whisker stimulation at 1-h superfusion of CSF and (A) after an additional 2-h administration of the the A 2A antagonist SCH-58261(0.1 mg/kg + 0.1 mg/kg/h, intravenous; n = 6), (B) the A 2B antagonist MRS-1754 (1 mg/kg, intravenous, + 1 mmol/L superfusion; n = 7), or (C) the A 3 antagonist MRS-1191 (1 mmol/L superfusion; n = 5). *P < 0.05 from the 1-h control response.
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However, addition of 14,15-EEZE to AIDA did produce a small decrement in the 60-sec average response compared with AIDA alone (Figure 10 ; n = 6), although the attenuation by AIDA alone was less than in the previous group with AIDA alone (Figure 9 ). Moreover, the combination of AIDA plus 14,15-EEZE reduced the response to 59717% of the baseline response (Figure 10 ), and this attenuation was not significantly different from the reduction to 52712% of the baseline response seen with the combination of AIDA plus alloxazine ( Figure 9 ). When AIDA and alloxazine were administered simultaneously, the LDF response was decreased to 59714% of the control response (Figure 11 ; n = 6). Addition of 14,15-EEZE did not produce a further decrease in the response.
Previous work has demonstrated that MS-PPOH and miconazole did not reduce the amplitude of somatosensory evoked potentials over cerebral cortex during electrical stimulation of the forepaw (Peng et al, 2002) . As a percent of the baseline response, the amplitude of the primary cortical evoked potential with contralateral forepaw stimulation was 121744% in a time-control group (n = 6), 114725% in a group superfused with 30 mmol/L 14,15-EEZE (n = 5), 89727% in a group superfused with 100 mmol/L AIDA (n = 6), 94721% in a group administered 1 mg/kg, intravenous, plus 1 mmol/L superfused ZM-241385 (n = 5), and 83728% in a group administered 1 mg/kg, intravenous, plus 1 mmol/L superfused alloxazine (n = 10). The evoked potential amplitude after drug treatment was not significantly different from the baseline response, and analysis of variance did not indicate a significant difference among groups after drug treatment. The lack of effect of AIDA is consistent with other findings showing that the suppressed LDF response A B C D E Figure 5 Percentage change of cortical LDF (7s.d.) averaged over a 60-sec period of whisker stimulation at 1-h superfusion of CSF and (A) after an additional 2 h of superfusion with the EET synthesis inhibitors MS-PPOH (n = 6) and (B) miconazole (n = 6) or (D) with the EET antagonists 14,15-EEZE-mSI (n = 7) and (E) 14,15-EEZE (n = 6). *P < 0.05 from the 1-h control response. In (C), segments of rat middle cerebral arteries were pressurized to 80 mm Hg and exposed to 30 mmol/L serotonin to preconstrict the arteries by B35%. Subsequent treatment with 100 and 300 nmol/L 14,15-EET produced dose-dependent dilation (n = 4) that was inhibited by 10 mmol/L 14,15-EEZE-mSI (n = 4). *P < 0.05 from control.
to forepaw stimulation with other Group I mGluR antagonists is not the result of suppression of evoked potentials (Zonta et al, 2003) .
Discussion
The major findings of this study are that (1) adenosine A 2B rather than A 2A or A 3 receptors play a significant role in coupling cortical blood flow to neuronal activity evoked by whisker stimulation; (2) EET antagonists inhibit the blood flow response, further supporting the role of EETs in neurovascular coupling; (3) the effect of an antagonist of A 2B receptors on the evoked flow response is not additive with the effect of an EET antagonist or synthesis inhibitor; (4) the effect of an antagonist of A 2B receptors is not additive with the effect of a mGluR antagonist on the flow response; and (5) combining A 2B , mGluR, and EET antagonists does not completely block the blood flow response to whisker stimulation. 
Adenosine Receptors
During functional activation elicited by sciatic nerve stimulation, pial arteriolar dilation is attenuated by the nonselective adenosine antagonists theophylline (Ko et al, 1990) and caffeine (Meno et al, 2005) . The selective A 2A receptor antagonist ZM-241385 was also effective at 1 mg/kg, although not with topical application at 1 mmol/L ). In addition, pial arteriolar dilation to topical glutamate was inhibited by ZM-241385 at CSF concentrations of 0.1 and 1 mmol/L or at an intravenous dose of 1 mg/kg (Iliff et al, 2003) . Likewise, topical ZM-241385 at 1 mmol/L attenutated pial arteriolar dilation AMPA with no further attenuation at 10 mmol/L (Ohata et al, 2006) . In this study, a combination of 1 mg/kg intravenous dose and 1 mmol/L continuous superfusion was used to assure adequate availability of the drug in the vasculature and parenchyma. Thus, the lack of effect of ZM-241385 on the LDF response to whisker stimulation in this study was unexpected. To address the possibility that subarachnoid superfusion diluted the drug, the outflow of radiolabeled ZM-241385 was measured. Over a 1-h period, the outflow concentration averaged 84% of the concentration in a standard cranial window. Thus, the concentration in the CSF with an inflow concentration of 1 mmol/L should have been well above the 0.1 mmol/L concentration shown to inhibit pial arteriolar responses to glutamate. Furthermore, the outflow concentration was 95% of the inflow concentration by 1 h, and extending the superfusion period for an additional hour did not inhibit the LDF response to whisker stimulation ( Figure 2B ). Other drugs that did inhibit the LDF response with 1 h of superfusion displayed no further inhibition with an additional hour of superfusion, thereby indicating adequate time for penetration into the underlying tissue. Hence, the dose and duration of ZM-241385 superfusion should have been adequate to discern an effect.
Another possibility is that the tissue monitored by LDF over a presumed 1-mm depth is not sensitive to Figure 10 Time course of 1-sec averages of cortical LDF (7s.d.; n = 6 rats), expressed as a percentage change from a 60-sec baseline recording, during 60 secs of whisker stimulation and 60 secs of recovery after 1-h superfusion of CSF, 1 h of AIDA superfusion, and 1 h of combined AIDA and 14,15-EEZE superfusion. Inset bar graph shows percentage change in LDF averaged over the 60-sec stimulation period. *P < 0.05 from control response; + P < 0.05 from AIDA alone. Figure 11 Time course of 1-sec averages of cortical LDF (7s.d.; n = 6 rats), expressed as a percentage change from a 60-sec baseline recording, during 60 secs of whisker stimulation and 60 secs of recovery after 1-h superfusion of CSF, 1 h of AIDA plus alloxazine administration, and 1 h of combined AIDA, alloxazine and 14,15-EEZE administration. Inset bar graph shows percentage change in LDF averaged over the 60-sec stimulation period. *P < 0.05 from control response.
A 2A receptor activation or that the antagonist is ineffective in blocking A 2A receptors in the underlying tissue. However, superfusion of the A 2A agonist CGS-21680 increased LDF, and the increase was nearly completely blocked by 1 mg/kg, intravenous, plus 1 mmol/L superfusion of ZM-241385. Alloxazine had no effect on this response. Thus, the dose and routes of administration of ZM-241385 were effective in inhibiting a selective A 2A vascular response. Although high doses of ZM-241385 can also inhibit A 2B receptors, the difference between the effects of ZM-241385 and alloxazine on the LDF response infers that ZM-241385 was not exerting an effect on A 2B receptors at the doses employed in this study. In support of ZM-241385 selectivity for A 2A receptors, ZM-241385 had no effect on the LDF response to 10 mmol/L NECA, a dose at which alloxazine largely suppressed the LDF response. A greater potency of alloxazine than ZM-241385 for inhibiting vasodilation to NECA has also been reported for pial arterioles (Shin et al, 2000) .
Lastly, the lack of effect of ZM-241385 on the LDF response to whisker stimulation was supported by the lack of effect of another A 2A antagonist SCH-58261. Curiously, others reported that topical ZM-241385 was ineffective in blocking pial arteriolar dilation to sciatic nerve stimulation at doses that blocked the dilation to glutamate (Iliff et al, 2003) . This incongruity raises the possibility that the positive effect of systemically administered ZM-241385 in inhibiting the pial arteriolar responses to sciatic nerve stimulation ) may be due to an indirect peripheral effect of systemic administration. However, our observation that systemic administration of SCH-58261 without CSF superfusion exerted no inhibitory effect on the LDF response indicates that a nonspecific effect of A 2A antagonism in other tissues is unlikely to have a major effect on neurovascular coupling. Together, our results indicate that A 2A receptors are not required for coupling cortical blood flow to neuronal activation. Any pial arteriolar dilation that is partially dependent on A 2A receptors during functional activation may help maintain blood flow in non-activated cortical areas surrounding the primary activated regions.
Another possibility for the lack of effect of A 2A antagonists is that intraparenchymal arterioles do not have functional A 2A receptors. However, penetrating arterioles in rat brain dilate in response to an A 2A receptor agonist, and dilation to adenosine is attenuated by ZM-241385 (Ngai et al, 2001) . It is interesting that dilation of penetrating arterioles to adenosine is greater than dilation to an A 2A agonist and that dilation to adenosine is not reduced by an A 1 or A 3 antagonist and is only partially reduced by ZM-241385. These findings indirectly imply that part of the dilation of intraparenchymal arterioles to adenosine is mediated by another receptor such as the A 2B receptor. In pial arterioles, the A 2B receptor antagonist alloxazine also attenuated dilation in response to adenosine (Shin et al, 2000) . A physiologic role of both A 2A and A 2B receptors has been implicated by the findings that both ZM-241385 and alloxazine attenuate pial arteriolar dilation to hypotension (Shin et al, 2000) and to AMPA receptor activation (Ohata et al, 2006) . The present results, showing that alloxazine and MRS-1754, but not A 2A antagonists, are effective in reducing a physiologic vascular response, appear unique. Because A 2A receptors have a higher affinity for adenosine than A 2B receptors, the differential activation of A 2B receptors is best explained by localized increases in adenosine restricted to the vicinity of A 2B receptors.
Neurons release ATP as a co-neurotransmitter, and astrocytes release ATP during propagation of Ca 2 + waves. Extracellular ATP is metabolized to adenosine by ecto-ATPase and ecto-5 0 -nucleotidase (Fields and Burnstock, 2006) , and ecto-ATPase appears to be localized near astrocyte hemichannels, where ATP is released (Joseph et al, 2003) . Astrocytes express various adenosine receptor subtypes (Fields and Burnstock, 2006) . Activation of A 2B receptors on astrocytes has been noted to increase intracellular Ca 2 + (Newman, 2005; Pilitsis and Kimelberg, 1998) and to potentiate Ca 2 + waves in astrocytes evoked by ATP (Alloisio et al, 2004; Jimenez et al, 1999) . Therefore, one explanation for the selective effect of A 2B antagonists in the present experiment is that activation of A 2B receptors on astrocytes or on vascular smooth muscle near astrocyte foot processes releasing ATP is important in the communication between neurons and arterioles.
Our observation that MRS-1191 had no effect on the LDF response to whisker stimulation is consistent with data that MRS-1191 does not inhibit dilation of intraparenchymal aterioles to adenosine (Ngai et al, 2001) . Thus, the functional role of A 3 receptors purported to be expressed in cerebral vessels (Di Tullio et al, 2004) remains unclear. An A 1 receptor antagonist had no effect on intraparenchymal dilation to adenosine (Ngai et al, 2001) or on pial arteriolar dilation to glutamate (Iliff et al, 2003) , but increased the dilatory response to sciatic nerve stimulation ). The primary role of A 1 receptors presumably is in presynaptic modulation of glutamate release. Because of the difficulty in dissociating whether changes in vascular responses are due to changes in neuronal activation or neurovascular coupling, an A 1 receptor antagonist was not tested in this study.
Adenosine Receptors and Metabotropic Glutamate Receptor
Increases in astrocyte Ca 2 + triggered by neuronal activation is thought to be initiated by glutamate acting on Group 1 mGluR on astrocytes (Filosa et al, 2004; Zonta et al, 2003) . The group I mGluR antagonists LY367385 and MPEP have been shown to reduce the LDF response to electrical forepaw stimulation (Zonta et al, 2003) . The current results, which show an attenuation of the LDF response to whisker stimulation by the group I mGluR antagonist AIDA, are consistent with this previous study. The new finding that alloxazine does not produce additional attenuation of the response, compared with AIDA alone, is consistent with the possibility of a sequential mechanism in which A 2B receptor activation promotes the Ca 2 + signaling that is initiated within astrocytes by mGluR activation. An alternative possibility that is also consistent with the data is that mGluR-induced increased Ca 2 + causes release of ATP at astrocyte end-feet (Simard et al, 2003) , where ATP might be converted into adenosine and act on vascular A 2B receptors.
Epoxyeicosatrienoic Acids
In isolated retina without blood perfusion, PPOH was found to markedly decrease arteriolar dilation evoked by natural light stimulus or by release of caged Ca 2 + or IP 3 in astrocytes, whereas indomethacin and aspirin were ineffective (Metea and Newman, 2006) . The presently observed decrease in the LDF response with MS-PPOH and miconazole confirms previous work with these distinct inhibitors of EET synthesis (Peng et al, 2002 (Peng et al, , 2004 . Decreases in the LDF response to whisker stimulation with the EET antagonists 14,15-EEZE and 14,15-EEZE-mSI further strengthen the role of EETs in coupling the neurovascular response to physiologic activation. Because the decrease in the LDF response with the antagonists was approximately the same as with the synthesis inhibitors, one might conclude that EET signaling depends on de novo synthesis rather than on release of preformed stores of EETs. However, it is also possible that preformed stores of EETs became depleted during the 1-h superfusion period of the synthesis inhibitors.
The ability of 14,15-EEZE-mSI to block relaxation by 14,15-EET in rat middle cerebral artery is consistent with work in bovine coronary artery (Gauthier et al, 2003) . Among the four regioisomers of EETs, 14,15-EEZE-mSI appears to be more selective for 14,15-EET and 5,6-EET (Gauthier et al, 2003) , whereas 14,15-EEZE inhibits relaxation to all four regioisomers (Gauthier et al, 2002) .The substantial inhibition of the LDF response to whisker stimulation with 14,15-EEZE-mSI is consistent with results showing that 14,15-EET is a major regioisomer synthesized in astrocytes (Alkayed et al, 1996; Amruthesh et al, 1993) and is either metabolized by epoxide hydrolase or incorporated into the phospholipid membrane (Shivachar et al, 1995) . Because of its broad spectrum potency, 14,15-EEZE, rather than 14,15-EEZE-mSI, was chosen for testing interactions with adenosine and mGluR pathways. Although 14,15-EEZE produced a small increase in LDF after the second hour of superfusion by a mechanism that is not clear, superfusion was restricted to 1 h in groups in which 14,15-EEZE was combined with other antagonists. Baseline LDF was unchanged in these other groups.
Epoxyeicosatrienoic Acids, Adenosine Receptors, and Metabotropic Glutamate Receptor Superfused 14,15-EEZE retained its ability to inhibit the LDF response to whisker stimulation in the presence of ZM-241385, but lost its inhibitory effect in the presence of alloxazine and combined alloxazine and AIDA. In addition, alloxazine produced no further inhibition of the LDF response in the presence of MS-PPOH. Although 14,15-EEZE did produce an additional inhibition of the response in the presence of AIDA, this additional inhibitory effect was small in magnitude and the overall attenuation with combined AIDA and 14,15-EEZE was comparable to that seen with EEZE alone or with AIDA alone in other groups. Thus, the effect of blocking EETs depends on the ability to activate mGluR and adenosine A 2B receptors. These results are consistent with an EET signaling pathway acting sequentially with mGluR and A 2B receptors, rather than by parallel, independent pathways. Glutamate stimulation of astrocytes causes release of EETs (Alkayed et al, 1997) , which could then hyperpolarize cerebrovascular smooth muscle by opening Ca 2 + -sensitive K + channels (Alkayed et al, 1996; Gebremedhin et al, 1992) . In astrocytes, EETs can serve as a Ca 2 + influx factor (Rzigalinski et al, 1999 ) and, during stimulation of mGluR, promote opening of Ca 2 + -sensitive K + channels, which will help maintain a hyperpolarized state favorable for Ca 2 + influx (Gebremedhin et al, 2003) . Therefore, EETs could act by multiple mechanisms to sustain mGluR-and A 2B -evoked Ca 2 + signaling within astrocytes and astrocyte-vascular coupling.
Combined treatment with AIDA, alloxazine, and 14,15-EEZE did not fully block the LDF response to whisker stimulation. Moreover, none of the drugs substantially delayed the onset of the LDF response. These results suggest that either (1) other pathways normally contribute to about half of the blood flow response with a rapid time constant, or (2) the mGluR, A 2B , and EET pathways normally contribute to more than half of the response, but new, back-up mechanisms with equally fast time constants are recruited when the primary mechanism is inhibited. In a previous study (Peng et al, 2002) , indomethacin did not significantly reduce the LDF response to whisker stimulation in the rat, and MS-PPOH attenuated, but did not completely block the response in the presence of indomethacin (Peng et al, 2002) . Metabolites of COX were not examined in this study, but could be responsible for the remaining response. COX-1 has been identified in perivascular astrocytes in mouse cortex, and use of a high dose of a COX-1 inhibitor was found to decrease arteriolar dilation to increased astrocytic Ca 2 + (Takano et al, 2006) . However, a lower dose of the COX-1 inhibitor was not effective in reducing the LDF response to whisker stimulation, and COX-1 null mice had a normal LDF response (Niwa et al, 2001) . Moreover, stimulation of COX-1 in astrocytes is presumed to be dependent on mGluR stimulation of Ca 2 + and subsequent activation of phospholipase A 2 (Zonta et al, 2003) . Thus, inhibition of mGluR may be expected to impede this COX-1-dependent pathway, and COX-1 may not contribute to the residual LDF response. Alternatively, COX-2 metabolites derived from neurons might bypass astrocyte signaling and directly dilate vascular smooth muscle (Niwa et al, 2000; Wang et al, 2005) and thereby be responsible for the remaining LDF response.
Adenosine and Nitric Oxide
Cortical activation leads to a rapid increase in NO, but the increase lasts only 2 secs (Buerk et al, 2003) and thus does not temporally correlate with the rapid decrease in LDF during the off-response. The transient increase in NO may permit vasodilation by other mediators, rather than act as a primary mediator of the cortical flow response to activation (Lindauer et al, 1999) . Combining L-NNA with MS-PPOH or miconazole did not eliminate the LDF response to forepaw stimulation (Peng et al, 2004) . Combining L-NNA and theophylline was reported to inhibit the LDF response to whisker stimulation by 58%, which was slightly greater than the 41% inhibition with theophylline alone (Dirnagl et al, 1994) . Application of adenosine or an A 2B agonist on the cortical surface was found to produce vasodilation that was partially dependent on NO and cGMP (Dirnagl et al, 1994; Shin et al, 2000) . In this study, alloxazine did not produce additional inhibition or complete blockage of the LDF response in the presence of L-NNA. This finding is consistent with the possibility that the adenosine A 2B mechanism involved in functional hyperemia depends on NO. However, our data do not distinguish whether adenosine acting on vascular smooth muscle A 2B receptors requires NO as a mediator or permissive enabler of vasodilation, or if adenosine acting on astrocyte A 2B receptors contributes to release of vasoactive arachidonic acid metabolites that, in turn, require NO as a permissive enabler of vasodilation. The lack of complete blockage of the LDF response when L-NNA is combined with theophylline, alloxazine, MS-PPOH, or miconazole suggests that the residual response presently seen after AIDA, alloxazine, and 14,15-EEZE is unlikely to be attributed to NO.
Anesthesia
Although the use of anesthesia is known to decrease the magnitude of the evoked CBF response (Nakao et al, 2001 ) and could influence the interaction of signaling pathways, this study demonstrates a proof of principle that the mGluR, A 2B , and EETs pathways are capable of regulating the CBF response to functional activation in a non-additive fashion. With chloralose anesthesia and the use of cranial windows, others reported an average increase in LDF during whisker stimulation in the rat in the range of 15 to 20% (Dirnagl et al, 1994; Irikura et al, 1994; Lindauer et al, 1999) . In this study with chloralose anesthesia and subarachnoid superfusion, the average response for each group generally fell into this range, although the LDF response displayed some variability among groups. However, the response was more reproducible within the same animal, and paired analysis permitted detection of moderate changes in the response.
In summary, this study demonstrates involvement of adenosine A 2B receptors in the coupling of cortical blood flow to neural activation. Further evidence supports previous work that implicates EETs and mGluR in the neurovascular coupling. The lack of additive inhibitory effects on the CBF response by combined antagonists is consistent with the mGluR, A 2B , and EET signaling in sequential pathways, possibly located in astrocytes.
